Drug Profile
Research programme: cancer therapeutics - Tapestry
Latest Information Update: 26 May 2008
Price :
$50
*
At a glance
- Originator Tapestry Pharmaceuticals
- Developer Supratek Pharma; Tapestry Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 18 Aug 2004 Preclinical trials in Cancer in USA (unspecified route)